课题基金 / 基金详情

EXPERIMENTAL CHEMOTHERAPY OF PROLIFERATIVE SKIN DISEASES

EXPERIMENTAL CHEMOTHERAPY OF PROLIFERATIVE SKIN DISEASES
增殖性皮肤病的实验化疗
批准号:
3152372
负责人:
MICHAEL M WICK
金额:
$12.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-04-01 至 1987-03-31

项目摘要

项目成果

MICHAEL M WICK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Psoriasis is a common and potentially debilitating disease, characterized by increased proliferation of skin. Several anti-proliferative agents, including methotrexate and hydroxyurea, are effective for the clinical control of this disease when given systemically. During the past 5 years, we have studied the anti-proliferative proper ties of o-dihydroxybenzene derivatives and have shown this effect to be mediated, in part, through inhibition of the enzymes ribonucleotide reductase and DNA polymerase. Since ribonucleotide reductase is central to the control of DNA synthesis in mammalian cells, we propose to study systemically the role of this enzyme and deoxyribonucleotide pool sizes in the control of the growth of human epidermal and related cells. We will also synthesize lipophilic analogs of known inhibitors of this enzyme as potential topical anti-psoriatic agents. Specifically, we will determine enzyme activity in normal and psoriatic skin, compare the levels of deoxyribonucleotides in normal and abnormal skin, and determine the relationship of ribonucleotide reductase and DNA polymerase in the control of DNA synthesis. We will also prepare 4 classes of derivatives, which include lipid-soluble analogs of hydroxyurea, thymidine, catechol, and guanazole. A series of long chain alkyl N-substituted derivatives of hydroxyurea, alkylphosphate esters of thymidine, alkylamino derivatives of catechol, and alkylacetyl derivatives of guanazole will be prepared. Bioassay will be conducted using highly differentiated squamous cell carcinoma cells in vitro, cultures of human epidermal cells, and nude mouse xenographs with human epidermis. These assays will confirm that the anti-proliferative activity is retained and that proper biophysical partition, indicating increased lipophilicity, has been achieved. Hopefully, the results of this proposal will permit us to understand the role of the important controlling enzyme ribonucleotide reductase in the growth and differentiation of human skin, as well as to evaluate its potential as a pharmacologic target for the topical chemotherapy of proliferative skin disease in man.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine.
ara-C、道诺霉素、羟基脲和 3,4-二羟基苄胺对完整 L1210 细胞中胸苷酸合酶的抑制作用。
DOI: --
发表时间: 1987
期刊: Anti-cancer drug design
影响因子: --
作者: [FitzGerald,GB, Ratliff,J, Wick,MM]
通讯作者: Wick,MM
Sequential inhibitory effects of antitumor agents related to levodopa and dopamine upon DNA synthetic enzymes.
左旋多巴和多巴胺相关抗肿瘤药物对 DNA 合成酶的连续抑制作用。
DOI: 10.1016/0006-2952(86)90525-3
发表时间: 1986
期刊: Biochemical pharmacology
影响因子: 5.8
作者: [Fitzgerald,GB, Wick,MM]
通讯作者: Wick,MM
Inhibition of ribonucleotide reductase by naturally occurring quinols from spores of Agaricus bisporus.
双孢蘑菇孢子中天然存在的醌醇对核糖核苷酸还原酶的抑制。
DOI: 10.1016/s0006-291x(84)80207-7
发表时间: 1984
期刊: Biochemical and biophysical research communications
影响因子: 3.1
作者: [FitzGerald,GB, Rosowsky,A, Wick,MM]
通讯作者: Wick,MM
The IAP BIR Domain: A Novel Target for Cancer Therapy
  • 批准号:
    6333989
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2001
  • 负责人:
    MICHAEL M WICK
  • 依托单位:
L-DOPA ANALOGS AS NEW ANTITUMOR AGENTS
  • 批准号:
    3166624
  • 项目类别:
  • 资助金额:
    $10.13万
  • 财政年份:
    1979
  • 负责人:
    MICHAEL M WICK
  • 依托单位:
L-DOPA ANALOGS AS NEW ANTITUMOR AGENTS
  • 批准号:
    3166625
  • 项目类别:
  • 资助金额:
    $12.53万
  • 财政年份:
    1979
  • 负责人:
    MICHAEL M WICK
  • 依托单位:
L-DOPA ANALOGS AS NEW ANTITUMOR AGENTS
  • 批准号:
    3166626
  • 项目类别:
  • 资助金额:
    $13.12万
  • 财政年份:
    1979
  • 负责人:
    MICHAEL M WICK
  • 依托单位:
海外基金